Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
534 | 14838 | 38.0 | 74% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ANDROGEN RECEPTOR | authKW | 1088963 | 9% | 38% | 1394 |
2 | PROSTATE CANCER | authKW | 506756 | 17% | 10% | 2570 |
3 | CASTRATION RESISTANT PROSTATE CANCER | authKW | 423841 | 2% | 60% | 342 |
4 | PROSTATE | journal | 398949 | 6% | 21% | 939 |
5 | ANDROGEN DEPRIVATION THERAPY | authKW | 367271 | 2% | 52% | 343 |
6 | ABIRATERONE | authKW | 303766 | 1% | 83% | 177 |
7 | ENZALUTAMIDE | authKW | 288637 | 1% | 84% | 168 |
8 | CABAZITAXEL | authKW | 223898 | 1% | 75% | 145 |
9 | ABIRATERONE ACETATE | authKW | 213955 | 1% | 85% | 122 |
10 | BICALUTAMIDE | authKW | 192976 | 1% | 62% | 152 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Urology & Nephrology | 122521 | 27% | 2% | 3973 |
2 | Endocrinology & Metabolism | 41228 | 21% | 1% | 3121 |
3 | Oncology | 37263 | 27% | 1% | 4014 |
4 | Andrology | 14301 | 2% | 2% | 298 |
5 | Cell Biology | 1601 | 7% | 0% | 1095 |
6 | Biochemistry & Molecular Biology | 1332 | 13% | 0% | 1862 |
7 | Chemistry, Medicinal | 501 | 3% | 0% | 374 |
8 | Anatomy & Morphology | 424 | 1% | 0% | 136 |
9 | Pharmacology & Pharmacy | 385 | 6% | 0% | 860 |
10 | Reproductive Biology | 292 | 1% | 0% | 183 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | UROL | 166465 | 20% | 3% | 3004 |
2 | GEORGE WHIPPLE CANC | 61887 | 1% | 36% | 84 |
3 | LANK GENITOURINARY ONCOL | 42407 | 0% | 33% | 62 |
4 | S REPROD BIOL | 30560 | 0% | 39% | 38 |
5 | BIOL SYST ANIM PROD | 29237 | 0% | 89% | 16 |
6 | PROSTATE CANC TARGETED THER Y GRP | 24726 | 0% | 63% | 19 |
7 | GENITOURINARY ONCOL SERV | 20432 | 0% | 16% | 64 |
8 | UROL ONCOL PROGRAM | 18865 | 0% | 37% | 25 |
9 | VANCOUVER PROSTATE | 18645 | 0% | 17% | 54 |
10 | CHEM THER EUT PROGRAM | 18135 | 0% | 55% | 16 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PROSTATE | 398949 | 6% | 21% | 939 |
2 | JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 42804 | 3% | 5% | 436 |
3 | PROSTATE CANCER AND PROSTATIC DISEASES | 35591 | 1% | 13% | 137 |
4 | EUROPEAN UROLOGY | 31567 | 2% | 5% | 335 |
5 | UROLOGY | 19233 | 3% | 2% | 396 |
6 | EUROPEAN UROLOGY SUPPLEMENTS | 19083 | 0% | 13% | 74 |
7 | CLINICAL GENITOURINARY CANCER | 17685 | 1% | 11% | 77 |
8 | JOURNAL OF UROLOGY | 17477 | 3% | 2% | 496 |
9 | BJU INTERNATIONAL | 16830 | 2% | 3% | 261 |
10 | MOLECULAR ENDOCRINOLOGY | 11034 | 1% | 3% | 176 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ANDROGEN RECEPTOR | 1088963 | 9% | 38% | 1394 | Search ANDROGEN+RECEPTOR | Search ANDROGEN+RECEPTOR |
2 | PROSTATE CANCER | 506756 | 17% | 10% | 2570 | Search PROSTATE+CANCER | Search PROSTATE+CANCER |
3 | CASTRATION RESISTANT PROSTATE CANCER | 423841 | 2% | 60% | 342 | Search CASTRATION+RESISTANT+PROSTATE+CANCER | Search CASTRATION+RESISTANT+PROSTATE+CANCER |
4 | ANDROGEN DEPRIVATION THERAPY | 367271 | 2% | 52% | 343 | Search ANDROGEN+DEPRIVATION+THERAPY | Search ANDROGEN+DEPRIVATION+THERAPY |
5 | ABIRATERONE | 303766 | 1% | 83% | 177 | Search ABIRATERONE | Search ABIRATERONE |
6 | ENZALUTAMIDE | 288637 | 1% | 84% | 168 | Search ENZALUTAMIDE | Search ENZALUTAMIDE |
7 | CABAZITAXEL | 223898 | 1% | 75% | 145 | Search CABAZITAXEL | Search CABAZITAXEL |
8 | ABIRATERONE ACETATE | 213955 | 1% | 85% | 122 | Search ABIRATERONE+ACETATE | Search ABIRATERONE+ACETATE |
9 | BICALUTAMIDE | 192976 | 1% | 62% | 152 | Search BICALUTAMIDE | Search BICALUTAMIDE |
10 | ESTRAMUSTINE | 186219 | 1% | 82% | 111 | Search ESTRAMUSTINE | Search ESTRAMUSTINE |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | TAN, MHE , LI, J , XU, HE , MELCHER, K , YONG, EL , (2015) ANDROGEN RECEPTOR: STRUCTURE, ROLE IN PROSTATE CANCER AND DRUG DISCOVERY.ACTA PHARMACOLOGICA SINICA. VOL. 36. ISSUE 1. P. 3 -23 | 141 | 74% | 33 |
2 | HEINLEIN, CA , CHANG, CS , (2004) ANDROGEN RECEPTOR IN PROSTATE CANCER.ENDOCRINE REVIEWS. VOL. 25. ISSUE 2. P. 276-308 | 203 | 52% | 752 |
3 | QUIGLEY, CA , DEBELLIS, A , MARSCHKE, KB , ELAWADY, MK , WILSON, EM , FRENCH, FS , (1995) ANDROGEN RECEPTOR DEFECTS - HISTORICAL, CLINICAL, AND MOLECULAR PERSPECTIVES.ENDOCRINE REVIEWS. VOL. 16. ISSUE 3. P. 271-321 | 176 | 67% | 855 |
4 | YUAN, X , CAI, C , CHEN, S , CHEN, S , YU, Z , BALK, SP , (2014) ANDROGEN RECEPTOR FUNCTIONS IN CASTRATION-RESISTANT PROSTATE CANCER AND MECHANISMS OF RESISTANCE TO NEW AGENTS TARGETING THE ANDROGEN AXIS.ONCOGENE. VOL. 33. ISSUE 22. P. 2815 -2825 | 118 | 74% | 64 |
5 | WATSON, PA , ARORA, VK , SAWYERS, CL , (2015) EMERGING MECHANISMS OF RESISTANCE TO ANDROGEN RECEPTOR INHIBITORS IN PROSTATE CANCER.NATURE REVIEWS CANCER. VOL. 15. ISSUE 12. P. 701 -711 | 99 | 73% | 55 |
6 | SHUKLA, GC , PLAGA, AR , SHANKAR, E , GUPTA, S , (2016) ANDROGEN RECEPTOR-RELATED DISEASES: WHAT DO WE KNOW?.ANDROLOGY. VOL. 4. ISSUE 3. P. 366 -381 | 160 | 76% | 0 |
7 | KOKONTIS, JM , LIAO, SS , (1999) MOLECULAR ACTION OF ANDROGEN IN THE NORMAL AND NEOPLASTIC PROSTATE.VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 55. VOL. 55. ISSUE . P. 219 -307 | 290 | 58% | 67 |
8 | FERRALDESCHI, R , WELTI, J , LUO, J , ATTARD, G , DE BONO, JS , (2015) TARGETING THE ANDROGEN RECEPTOR PATHWAY IN CASTRATION-RESISTANT PROSTATE CANCER: PROGRESSES AND PROSPECTS.ONCOGENE. VOL. 34. ISSUE 14. P. 1745 -1757 | 115 | 76% | 17 |
9 | SHAFI, AA , YEN, AHE , WEIGEL, NL , (2013) ANDROGEN RECEPTORS IN HORMONE-DEPENDENT AND CASTRATION-RESISTANT PROSTATE CANCER.PHARMACOLOGY & THERAPEUTICS. VOL. 140. ISSUE 3. P. 223-238 | 137 | 65% | 51 |
10 | DE BONO, JS , LORENTE, D , MATEO, J , ZAFEIRIOU, Z , SMITH, AD , SANDHU, S , FERRALDESCHI, R , (2015) SWITCHING AND WITHDRAWING HORMONAL AGENTS FOR CASTRATION-RESISTANT PROSTATE CANCER.NATURE REVIEWS UROLOGY. VOL. 12. ISSUE 1. P. 37 -47 | 86 | 97% | 17 |
Classes with closest relation at Level 2 |